SCHEMBL506934

SCHEMBL506934

CC(C)(C)OC(=O)C(N)c1ccc(C(=O)O)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ANPEP P15144 1/20 0.45
MAPT P10636 2/20 0.42
NR1H4 Q96RI1 1/20 0.41
TP53 P04637 1/20 0.40
TSHR P16473 1/20 0.40
SRD5A2 P31213 3/20 0.40
KMT2A Q03164 2/20 0.40
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
ALDH1A1 P00352 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
GRM1 Q13255 2/20 0.38
MEN1 O00255 1/20 0.38
CYP1A2 P05177 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
RXRA P19793 2/20 0.38
RXRB P28702 2/20 0.38
SLC7A5 Q01650 1/20 0.37
ELANE P08246 1/20 0.37
RXRG P48443 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3013541 0.91 RARB (0.51) ANPEPMAPTNR1H4SRD5A2KMT2A
SCHEMBL2874909 0.87 CPT1B (0.39) ANPEPMAPTKMT2ACA1CA2
SCHEMBL305032 0.84 L3MBTL1 (0.45) MAPTKMT2AALDH1A1SMN1; SMN2MEN1
SCHEMBL30065221 0.84 L3MBTL1 (0.45) MAPTKMT2AALDH1A1SMN1; SMN2MEN1
SCHEMBL594359 0.84 L3MBTL1 (0.45) MAPTKMT2AALDH1A1SMN1; SMN2MEN1
SCHEMBL2569650 0.84 MAPT (0.45) MAPTTSHRCA1CA2ALDH1A1
SCHEMBL5414405 0.83 MIF (0.40) MAPTKMT2ACYP1A2TDP1ELANE
SCHEMBL2357009 0.83 LMNA (0.37) MAPTTSHRKMT2AALDH1A1CYP1A2
SCHEMBL9995953 0.83 MIF (0.40) MAPTKMT2ACYP1A2TDP1ELANE
Hydrochloric Acid SCHEMBL304679 0.83 ATM (0.44) MAPTKMT2AALDH1A1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 319 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122029157-A Bilobalide derivatives for the treatment of neurological diseases and cancers 香港中文大学 2026-05-12 CN claimed
US-20250144069-A1 BILOBALIDE DERIVATIVE COMPOUNDS FOR TREATING NEUROLOGICAL DISEASES AND CANCERS THE CHINESE UNIVERSITY OF HONG KONG (CN) 2025-05-08 US claimed
WO-2025031304-A1 BILOBALIDE DERIVATIVE COMPOUNDS FOR TREATING NEUROLOGICAL DISEASES AND CANCERS THE CHINESE UNIVERSITY OF HONG KONG (CN) 2025-02-13 WO claimed
CN-122029157-A Bilobalide derivatives for the treatment of neurological diseases and cancers 香港中文大学 2026-05-12 CN disclosed
US-20260000781-A1 FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF CIDARA THERAPEUTICS INC (US) 2026-01-01 US disclosed
US-20260001904-A1 COMPOUNDS AND METHODS FOR LIQUID PHASE OLIGONUCLEOTIDE SYNTHESIS HONGENE BIOTECH CORP (US) 2026-01-01 US disclosed
US-12459970-B2 Progesterone analogs and uses related thereto EMORY UNIVERSITY (US) 2025-11-04 US disclosed
US-12415829-B2 Progesterone phosphate analogs and uses related thereto EMORY UNIVERSITY (US) 2025-09-16 US disclosed
EP-4551563-A2 FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF CIDARA THERAPEUTICS, INC. (US) 2025-05-14 EP disclosed
US-20250144069-A1 BILOBALIDE DERIVATIVE COMPOUNDS FOR TREATING NEUROLOGICAL DISEASES AND CANCERS THE CHINESE UNIVERSITY OF HONG KONG (CN) 2025-05-08 US disclosed
CN-119816487-A FC conjugates comprising CD73 inhibitors and uses thereof 奇达拉治疗公司 2025-04-11 CN disclosed
US-5476847-A Treating cardiovascular, gastrointestinal, urogenital disorders SCHERING CORPORATION (US) 1995-12-19 US disclosed
EP-0674623-A1 BICYCLIC FIBRINOGEN ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1995-10-04 EP disclosed
EP-0672034-A1 BENZIMIDAZOLE COMPOUNDS WHICH INHIBIT PLATELET AGGREGATION SMITHKLINE BEECHAM CORPORATION (US) 1995-09-20 EP disclosed
WO-1994014776-A2 BICYCLIC FIBRINOGEN ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1994-07-07 WO disclosed
WO-1994012478-A1 BENZIMIDAZOLE COMPOUNDS WHICH INHIBIT PLATELET AGGREGATION SMITHKLINE BEECHAM CORPORATION (US) 1994-06-09 WO disclosed
EP-0454773-A1 NOVEL PRODRUG DERIVATIVES OF BIOLOGICALLY ACTIVE AGENTS CONTAINING HYDROXYL GROUPS OR NH-ACIDIC GROUPS Bundgaard, Hans (DK) 1991-11-06 EP disclosed
US-4954512-A Anti-ulcer composition Okamoto, Shosuke (JP) 1990-09-04 US disclosed
WO-1990008128-A1 NOVEL PRODRUG DERIVATIVES OF BIOLOGICALLY ACTIVE AGENTS CONTAINING HYDROXYL GROUPS OR NH-ACIDIC GROUPS BUNDGAARD HANS (DK) 1990-07-26 WO disclosed
EP-0317959-A2 Anti-ulcer composition Okamoto, Shosuke (JP) 1989-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260001904-A1 COMPOUNDS AND METHODS FOR LIQUID PHASE OLIGONUCLEOTIDE SYNTHESIS POLR2H, POLR2E, NSUN2 ANPEP 4336/4885MAPT 4579/4885NR1H4 453/4885
US-12415829-B2 Progesterone phosphate analogs and uses related thereto PGR, SHBG, PGRMC2 ANPEP 1131/4885MAPT 2182/4885NR1H4 1138/4885
US-12459970-B2 Progesterone analogs and uses related thereto PGR, SHBG, PGRMC1 ANPEP 1169/4885MAPT 1787/4885NR1H4 946/4885
US-20250144069-A1 BILOBALIDE DERIVATIVE COMPOUNDS FOR TREATING NEUROLOGICAL DISEASES AND CANCERS BTD, BCHE, BRCA1 ANPEP 3919/4885MAPT 33/4885NR1H4 2968/4885
US-20260000781-A1 FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF FCGR2A, FCGR1A, FCGR3B ANPEP 454/4885MAPT 4879/4885NR1H4 1856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.